Lion Point Capital’s MoonLake Immunotherapeutics MLTX Stock Holding History

Lion Point Capital’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.31M	Hold	67,500	–	–	6.29%	3
2026 Q1	$1.26M	Hold	67,500	–	–	7.52%	2
2025 Q4	$890K	Hold	67,500	–	–	4.6%	3
2025 Q3	$484K	Buy	+67,500	New	+$3.52M	2.75%	18

Other funds holding MLTX

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Jupiter Topco New York $245B AUM

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Lion Point Capital's MLTX Position: Q2 2026 in Review

Lion Point Capital held its MoonLake Immunotherapeutics (MLTX) position steady in Q2 2026 at 67,500 shares worth $1.31M. The position accounts for 6.29% of the portfolio, ranked #3.

Lion Point Capital first reported a position in MLTX in Q3 2025 and has held it in 4 quarters since. 173 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

Lion Point Capital held 67,500 shares of MoonLake Immunotherapeutics worth $1.31M as of Q2 2026.
Lion Point Capital left its MoonLake Immunotherapeutics share count unchanged in Q2 2026.
MoonLake Immunotherapeutics made up 6.29% of Lion Point Capital's portfolio in Q2 2026, its #3 holding.
Lion Point Capital first reported a position in MoonLake Immunotherapeutics in Q3 2025 and has held it in 4 quarters since.
173 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on Lion Point Capital's 13F filing for Q2 2026, filed 14 Aug 2026.